Pulnovo Medical develops a proprietary Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy aimed at modulating sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. The company reports about 1,500 PADN procedures performed globally and regulatory approvals in seven countries, and it is advancing commercialization across the European Union, Middle East, and China. Pulnovo's therapy has been referenced in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines, and clinical studies are ongoing in Europe and Asia with U.S. IDE trials recently initiated. In the United States the company has received FDA Breakthrough Device designation and has started two fully approved IDE trials, including the PULSE-LHD trial. Following the $100 million strategic financing led by Medtronic, Pulnovo plans to use proceeds to support clinical development, regulatory submissions, international commercialization, and continued technology investment. The company is also expanding its leadership team, hiring a Chief Strategy Officer to strengthen ties with global capital markets and industry partners.

Total raised

$200M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026